Kevin Jon Williams

List of Publications by Year in Descending Order

80 papers	7,828 citations	44 h-index	86 g-index
86 ext. papers	8,506 ext. citations	9.5 avg, IF	6.02 L-index

#	Paper	IF	Citations
80	A randomized controlled trial of an innovative, user-friendly, interactive smartphone app-based lifestyle intervention for weight loss. *Obesity Science and Practice*, **2021**, 7, 555-568	2.6	0
79	Immunological and clinical heterogeneity in cutaneous lupus erythematosus. *British Journal of Dermatology*, **2021**, 185, 480-481	4	1
78	CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. *Modern Pathology*, **2020**, 33, 2614-2625	9.8	5
77	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. *Modern Pathology*, **2020**, 33, 2397-2406	9.8	9
76	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions. *Modern Pathology*, **2020**, 33, 2307-2317	9.8	8
75	An oxide transport chain essential for balanced insulin action. *Atherosclerosis*, **2020**, 298, 42-51	3.1	3
74	Guenther Boden, MD (1935-2015): A Pioneer in Human Studies of Nutrition and Obesity-And the Mystery of Insulin Resistance for Handling Glucose. *Diabetes Care*, **2020**, 43, 2910-2915	14.6	
73	Diabetes-Related Fracture Risk Is Different in African Americans Compared With Hispanics and Caucasians. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 5729-5736	5.6	5
72	Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. *European Heart Journal*, **2018**, 39, 2562-2573	9.5	72
71	Novel Insights into How Overnutrition Disrupts the Hypothalamic Actions of Leptin. *Frontiers in Endocrinology*, **2018**, 9, 89	5.7	16
70	Suppression of Hepatic FLOT1 (Flotillin-1) by Type 2 Diabetes Mellitus Impairs the Disposal of Remnant Lipoproteins via Syndecan-1. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 102-113	8.4	14
69	Imbalanced insulin action in chronic over nutrition: Clinical harm, molecular mechanisms, and a way forward. *Atherosclerosis*, **2016**, 247, 225-82	3.1	51
68	Translocation of Endogenous Danger Signal HMGB1 From Nucleus to Membrane Microvesicles in Macrophages. *Journal of Cellular Physiology*, **2016**, 231, 2319-26	7	37
67	The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. *Current Opinion in Lipidology*, **2016**, 27, 473-83	4.4	217
66	Insulin regulates the unfolded protein response in human adipose tissue. *Diabetes*, **2014**, 63, 912-22	0.9	28
65	Biglycan deficiency: increased aortic aneurysm formation and lack of atheroprotection. *Journal of Molecular and Cellular Cardiology*, **2014**, 75, 174-80	5.8	19
64	Response to comment on Boden et al. Insulin regulates the unfolded protein response in human adipose tissue. Diabetes 2014;63:912-922. *Diabetes*, **2014**, 63, e2	0.9	

63	Decreased body fat, elevated plasma transforming growth factor-β levels, and impaired BMP4-like signaling in biglycan-deficient mice. *Connective Tissue Research*, **2013**, 54, 5-13	3.3	10
62	Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke. *American Journal of Pathology*, **2013**, 182, 1552-62	5.8	85
61	Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor. *Journal of Biological Chemistry*, **2013**, 288, 13988-13999	5.4	58
60	NOX4 pathway as a source of selective insulin resistance and responsiveness. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 1236-45	9.4	44
59	What does HDL do? A new mechanism to slow atherogenesis--but a new problem in type 2 diabetes mellitus. *Atherosclerosis*, **2012**, 225, 36-8	3.1	7
58	Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia. *Hepatology*, **2012**, 55, 1746-53	11.2	36
57	Microvesicles: potential markers and mediators of endothelial dysfunction. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2012**, 19, 121-7	4	57
56	Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns: mechanisms of formation, action, and detoxification. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 2113-21	9.4	58
55	The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia. *Current Opinion in Lipidology*, **2012**, 23, 334-44	4.4	30
54	Tobacco smoke induces the generation of procoagulant microvesicles from human monocytes/macrophages. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 1818-24	9.4	107
53	Recent insights into factors affecting remnant lipoprotein uptake. *Current Opinion in Lipidology*, **2010**, 21, 218-28	4.4	68
52	Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. *Hepatology*, **2010**, 52, 1957-67	11.2	43
51	HDL as a contrast agent for medical imaging. *Clinical Lipidology*, **2009**, 4, 493-500		34
50	Some things just have to be done in vivo: GPIHBP1, caloric delivery, and the generation of remnant lipoproteins. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 792-5	9.4	8
49	Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 1723-30	9.4	110
48	Rapid regression of atherosclerosis: insights from the clinical and experimental literature. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 91-102		143
47	Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 5862-7	11.5	103
46	Autophagy of an oxidized, aggregated protein beyond the ER: a pathway for remarkably late-stage quality control. *Autophagy*, **2008**, 4, 721-3	10.2	19

45	Molecular processes that handle -- and mishandle -- dietary lipids. *Journal of Clinical Investigation*, **2008**, 118, 3247-59	15.9	129
44	Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 430-5	9.4	96
43	Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. *Circulation*, **2007**, 116, 1832-44	16.7	916
42	Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. *Current Opinion in Lipidology*, **2007**, 18, 443-50	4.4	26
41	Decorin deficiency enhances progressive nephropathy in diabetic mice. *American Journal of Pathology*, **2007**, 171, 1441-50	5.8	68
40	Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. *Nano Letters*, **2006**, 6, 2220-4	11.5	142
39	Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2687-94	15.4	22
38	Lipoprotein retention--and clues for atheroma regression. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1536-40	9.4	108
37	Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. *Journal of Biological Chemistry*, **2005**, 280, 18336-40	5.4	85
36	Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. *Diabetes*, **2005**, 54, 1116-22	0.9	24
35	Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. *Journal of the American Chemical Society*, **2004**, 126, 16316-7	16.4	271
34	Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. *Journal of Clinical Investigation*, **2004**, 113, 1277-87	15.9	197
33	Adam□ curse A future without men. *Journal of Clinical Investigation*, **2004**, 114, 870-870	15.9	78
32	Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. *Journal of Virology*, **2003**, 77, 12140-51	6.6	79
31	Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. *Blood*, **2002**, 99, 3613-22	2.2	69
30	Atherosclerosis and inflammation. *Science*, **2002**, 297, 521-2	33.3	51
29	The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. *Journal of Biological Chemistry*, **2001**, 276, 27855-63	5.4	156
28	Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. *Current Opinion in Lipidology*, **2001**, 12, 477-87	4.4	69

27	Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 8681-6	11.5	138
26	Perlecan heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism. *Journal of Biological Chemistry*, **2000**, 275, 25742-50	5.4	93
25	Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1033-9	9.4	35
24	Myofibroblast involvement in glycosaminoglycan synthesis and lipid retention during coronary repair. *Journal of Vascular Research*, **2000**, 37, 399-407	1.9	17
23	Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function. *Human Molecular Genetics*, **2000**, 9, 1967-76	5.6	35
22	Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 2648-58	9.4	102
21	Role of macrophage glycosaminoglycans in the cellular catabolism of oxidized LDL by macrophages. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 542-53	9.4	27
20	The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. *Journal of Biological Chemistry*, **1998**, 273, 18250-9	5.4	187
19	Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. *Journal of Biological Chemistry*, **1998**, 273, 2738-46	5.4	258
18	Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. *Journal of Biological Chemistry*, **1998**, 273, 4081-8	5.4	196
17	Improving the NRMP board: why not direct representation? National Resident Matching Program. *Academic Medicine*, **1998**, 73, 623-4	3.9	2
16	The response-to-retention hypothesis of atherogenesis reinforced. *Current Opinion in Lipidology*, **1998**, 9, 471-4	4.4	265
15	Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. *Current Opinion in Lipidology*, **1997**, 8, 253-62	4.4	107
14	Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 2132-9	9.4	44
13	UVB irradiation alters cellular responses to cytokines: role in extracellular matrix gene expression. *Journal of Investigative Dermatology*, **1997**, 108, 290-4	4.3	26
12	Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 383-93	9.4	40
11	The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. *Journal of Clinical Investigation*, **1997**, 100, 1611-22	15.9	195
10	Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. *Journal of Biological Chemistry*, **1996**, 271, 18431-6	5.4	234

9	Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. *Journal of Clinical Investigation*, **1996**, 98, 1455-64	15.9	249
8	The response-to-retention hypothesis of early atherogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 551-61	9.4	1042
7	Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia. *Journal of Clinical Investigation*, **1991**, 88, 1300-6	15.9	58
6	Macrophage cholesterol removal by triglyceride-phospholipid emulsions. *Biochemical and Biophysical Research Communications*, **1988**, 155, 709-13	3.4	10
5	Low density lipoprotein receptor-independent hepatic uptake of a synthetic, cholesterol-scavenging lipoprotein: implications for the treatment of receptor-deficient atherosclerosis. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 242-6	11.5	30
4	Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein. *Journal of Clinical Investigation*, **1987**, 79, 1217-25	15.9	166
3	Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages. *Journal of Clinical Investigation*, **1987**, 79, 1466-72	15.9	31
2	Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. *Perspectives in Biology and Medicine*, **1984**, 27, 417-31	1.5	97
1	An analysis of the resident match. *New England Journal of Medicine*, **1981**, 304, 1165-6	59.2	5